Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection.

Background: This study aimed to consider the main risk factors related to adverse clinical outcomes in MS patients with COVID-19.

Methods: Using the electronic health records systems, this is a cross-sectional study of two years of hospital admissions in terms of COVID-19 in Iran from March 2019 to August 2021. The severities of COVID-19 outcomes were admitted to ICU, hospitalization days, and in-hospital mortality.